Colossal Biosciences Seeks $20B-$30B Valuation in Funding

Colossal Biosciences, the ambitious firm aiming to resurrect extinct species, is reportedly in advanced discussions for a significant funding round that could value the company between $20 billion and $30 billion. This potential valuation marks a substantial leap from its previous funding in early 2025, which pegged the company at $10.2 billion, suggesting a doubling or even tripling of its market worth.

While specifics regarding the lead investor and the total capital to be raised remain undisclosed, the five-year-old startup has demonstrated early commercial traction. CEO and co-founder Ben Lamm outlined three key revenue streams. One involves offering its advanced conservation technologies to governmental bodies, with the United States and the United Arab Emirates already listed as clients. The UAE's recent $60 million investment underscores international interest in Colossal's unique scientific endeavors.

Looking ahead, Colossal Biosciences plans to tap into the burgeoning market for biodiversity credits, a mechanism analogous to carbon credits. Success in reintroducing species like the woolly mammoth or the dodo into their native ecosystems would unlock this revenue stream, positioning the company at the forefront of ecological restoration and conservation finance. This innovative approach could redefine the economic incentives for preserving biodiversity.

The company's scientific prowess is further evidenced by its strategic spin-offs. Three distinct entities are commercializing Colossal's core technologies: Breaking focuses on plastic degradation solutions, Form Bio, a computational biology platform, has already secured $30 million in funding, and Astromech, specializing in AI-driven predictive modeling for life sciences, achieved a $2 billion valuation in March. These ventures highlight the broad applicability of Colossal's scientific foundation, extending beyond de-extinction.

Colossal Biosciences continues to expand its ambitious project portfolio, recently adding the blue antelope as its sixth target species for potential reintroduction. Concurrently, its non-profit arm, the Colossal Foundation, is actively engaged in conservation efforts, including a partnership with the University of Tasmania to protect Tasmanian devils from a devastating facial tumor disease. CEO Ben Lamm anticipates the company's artificial animal mother technology will be operational next year, with potential future applications in human fertility treatments.

The company's fundraising efforts coincide with a broader surge in investment across deep-tech sectors, including longevity and alternative energy. Despite past controversies, such as its announcement to genetically recreate the African wild dog, industry observers note that the valuable technologies being developed by Colossal Biosciences may justify its significant valuation. The firm's ability to generate revenue and spin off successful ventures provides a strong foundation for its ambitious, long-term vision.